AstraZeneca (AZN) to Acquire Vaccine Maker Icosavax for $1.1B
https://www.zacks.com/stock/news/2196741/astrazeneca-azn-to-acquire-vaccine-maker-icosavax-for-1-1b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196741
Dec 12, 2023 - AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Icosavax, for a total deal value of up to $1.1 billion.
0
Sanofi (SNY) Terminates Pompe Disease Deal as FTC Objects
https://www.zacks.com/stock/news/2196713/sanofi-sny-terminates-pompe-disease-deal-as-ftc-objects?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196713
Dec 12, 2023 - Sanofi (SNY) decides to end the licensing deal with Maze Therapeutics for MZE001, a phase II ready oral tablet for Pompe disease, due to the FTC's decision to block the deal.
0
Sanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus
https://www.zacks.com/stock/news/2195113/sanofi-sny-posts-upbeat-long-term-outlook-enhances-r-d-focus?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195113
Dec 07, 2023 - Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immunology.
0